Bengaluru-based firm develops nanoemulsion intra-nasal platform and gets international patent

Bengaluru-based Synergia Biosciences unveiled a nanotechnology-based intra-nasal platform of medicine for brain-related disorders on Thursday

July 21, 2022 08:06 pm | Updated 08:06 pm IST - Bengaluru

The nanoemulsion platform presently is best suited to treat various brain-related disorders. 

The nanoemulsion platform presently is best suited to treat various brain-related disorders.  | Photo Credit: Getty Images/iStockphoto

City-based Synergia Biosciences unveiled a nanotechnology-based intra-nasal platform of medicine for brain-related disorders on Thursday.

It has acquired patents for the same in the United States of America, the European Union, India, and Japan. 

Synergia Biosciences said they have developed the platform in which lipophilic drugs can be dissolved for the intra-nasal spray mode of administering to patient.

“We have patented the composition of the platform and the process to arrive at that,” Sambratha Shetty, Chief Operating Officer, Synergia Biosciences said. 

The nanoemulsion platform presently is best suited to treat various brain-related disorders from cluster headaches, migraine, schizophrenia, dementia, epilepsy, Alzheimer’s and vertigo, binge drinking, depression, among others.

“One of the biggest challenges in drugs treating brain-related disorders is that it is very difficult to make the drug reach the target area. But with the intra-nasal route, it bypasses the first pass metabolism, increases bioavailability of the drug, and causes rapid absorption (less than 5 minutes),” Ms. Shetty explained.

Synergia has stabilised the nanoemulsion for four drugs: two antipsychotic ones, an analgesic, and an antiemetic. The same platform can be tweaked to carry vaccines and insulin, Synergia claimed. 

“The technology is non-invasive and mainly cost-effective. It is an affordable way to treat multiple diseases. This is a strategic technology which will help India treat multiple diseases at an affordable cost,” said Tobby Simon of Synergia Foundation.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.